Clinical Trials on SARS-CoV-2 Pneumonia in China

Total 79 results

Peking University
Centers for Disease Control and Prevention, China; Beijing Pinggu District... and other collaborators

Completed

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 2)

SARS-CoV-2

China
Peking University
Centers for Disease Control and Prevention, China; Beijing Pinggu District... and other collaborators

Completed

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 1)

SARS-CoV-2

China
Argorna Pharmaceuticals Co., LTD

Completed

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

SARS-CoV-2

China
Argorna Pharmaceuticals Co., LTD

Completed

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
Zhejiang Provincial Center for Disease Control and Prevention

Not yet recruiting

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Active, not recruiting

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention

Completed

Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People

SARS-CoV-2

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

SARS-CoV-2

China
Zhongnan Hospital

Recruiting

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

SARS-CoV-2 | Safety | Immunotoxicity

China
Ascletis Pharmaceuticals Co., Ltd.

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

SARS CoV 2 Infection

China
First Affiliated Hospital Xi'an Jiaotong University

Completed

Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2) (FASTER)

SARS CoV 2 Infection

China
Cancer Institute and Hospital, Chinese Academy...
Yunnan Center for Disease Control and Prevention

Recruiting

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above

SARS-CoV2 Infection

China
Children's Hospital of Fudan University

Terminated

Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai

SARS-CoV2 Infection | Neonatal Infection | Outcomes

China
Peking Union Medical College Hospital

Completed

Association Between Post-covid Infection Status and Perioperative Morbidity: A Ambispective Cohort Study

COVID-19 | Complication of Surgical Procedure | Complication,Postoperative | Sars-CoV-2 Infection | Complication of Anesthesia

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Recruiting

Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
The Second Affiliated Hospital of Chongqing Medical...

Recruiting

The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects

SARS-CoV-2 | Prevention

China
Chongqing Medical University

Completed

Prognostic Factors of Patients With COVID-19

SARS-CoV-2 | Outcome, Fatal

China
AstraZeneca

Completed

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Completed

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

SARS-CoV-2

China
WestVac Biopharma Co., Ltd.

Completed

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

COVID-19 | SARS-CoV-2 Pneumonia

China
Ono Pharmaceutical Co. Ltd

Completed

A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

SARS-CoV-2 Infection (COVID-19)

Japan
Shanghai Henlius Biotech
Huashan Hospital; Shanghai Fosun Pharmaceutical Industrial Development Co.... and other collaborators

Recruiting

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Ousehold in China

COVID-19

China
Beijing Ditan Hospital

Completed

A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19

COVID-19 | SARS-CoV-2 Infection

China
BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Completed

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

SARS-CoV-2

China
Cancer Institute and Hospital, Chinese Academy...
Hubei Provincial Center for Disease Control and Prevention

Recruiting

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)

SARS-CoV-2 Infection

China
Cancer Institute and Hospital, Chinese Academy...
Yunnan Center for Disease Control and Prevention

Recruiting

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above

SARS-CoV-2 Infection

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

COVID-19 Vaccine Induced Adaptive Immune Responses

COVID-19 | SARS-CoV-2 | Vaccine

China
WestVac Biopharma Co., Ltd.
West China Hospital

Completed

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

China
Huoshenshan Hospital
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

COVID-19

China
Capital Medical University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Suspended

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

COVID-19 | SARS-CoV-2

China
The Ninth Hospital of Nanchang
Ascletis Pharmaceuticals Co., Ltd.

Completed

Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

COVID-19

China
Capital Medical University

Terminated

A Trial of Remdesivir in Adults With Severe COVID-19

COVID-19 | SARS-CoV-2 | Remdesivir

China
Sinocelltech Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

COVID-19 | SARS-CoV-2 Infection

China
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
Zhejiang ACEA Pharmaceutical Co. Ltd.

Completed

Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

SARS-CoV-2 Infection

China
Bio-Thera Solutions

Completed

Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects

SARS-CoV-2 Infection

China
Ruijin Hospital

Recruiting

Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers

Covid19 | SARS-CoV-2 Infection

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
Southeast University, China
Hohhot First Hospital, Hohhot, Inner Mongolia, China

Recruiting

The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

SARS-CoV-2 Infection

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.

SARS-CoV-2

China
Beijing Ditan Hospital

Completed

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

SARS-CoV-2 Infection

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination

SARS-CoV-2 | COVID-19 Vaccine

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

SARS-CoV-2 Infection

China
Peking Union Medical College Hospital

Recruiting

Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)

COVID-19 | SARS-CoV-2

China
Yu Qin

Active, not recruiting

An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Prevention of COVID-19 Caused by SARS-CoV-2

China
University of Sargodha
Shanghai Jiao Tong University School of Medicine; Shanghai General Hospital... and other collaborators

Completed

Montelukast - a Treatment Choice for COVID-19

Covid19 | SARS-CoV-2 Infection

China, Pakistan
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China

Clinical Trials on SARS-CoV-2 Pneumonia in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations